[1] O'Grady TJ,Gates MA,Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011[J].Int J Cancer,2015,137(11):2664-2673. [2] 张波,徐景竹,吴琼.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:超声部分[J].中国癌症杂志,2016,26(1):19-24. [3] Liu M,Ruan M,Chen L.Update on the molecular diagnosis and targeted therapy of thyroid cancer[J].Med Oncol,2014,31(6):973. [4] Nikiforov YE.Thyroid carcinoma:molecular pathways and therapeutic targets[J].Modern Pathol,2008,21(Suppl 2):S37-S43. [5] Nucera C,Porrello A,Antonello ZA,et al.B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression[J].Proc Natl Acad Sci USA,2010,107(23):10649-10654. [6] Kim BA,Jee HG,Yi JW,et al.Expression profiling of a human thyroid cell Line Stably Expressing the BRAFV600E Mutation[J].Cancer Genomics Proteomics,2017,14(1):53-67. [7] Jung CK,Im SY,Kang YJ,et al.Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma[J].Thyroid,2012,22(8):791-797. [8] Xing M.BRAF mutation in thyroid cancer[J].EndocrRelat Cancer,2005,12(2):245-262. [9] 石臣磊,秦华东,丁超,等.鼠类肉瘤滤过性毒菌致癌同源体B1 V600 E基因突变与甲状腺乳头状癌中央区淋巴结转移的关系[J].中华肿瘤杂志,2015,37(2):123-127. [10] 王波,赵文新.ret/PTC3基因重排在甲状腺癌中的作用机制及其研究进展[J].中华实验外科杂志,2013,30(10):2241-2242. [11] Penna GC,Vaisman F,Vaisman M,et al.Molecular markers involved in tumorigenesis of thyroid carcinoma:focus on aggressive histotypes[J].Cytogenet Genome Res,2016,150(3/4):194-207. [12] Su X,Li Z,He C,et al.Radiation exposure,young age,and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer:a meta-analysis[J].Oncotarget,2016,7(13):16716-16730. [13] Figlioli G,Landi S,Romei C,et al.Medullary thyroid carcinoma (MTC) and RET proto-oncogene:mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form[J].Mutat Res,2013,752(1):36-44. [14] Romei C,Cosci B,Renzini G,et al.RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)[J].Clin Endocrinol(Oxf),2011,74(2):241-247. [15] Ciriello G,Cerami E,Sander C,et al.Mutual exclusivity analysis identifies oncogenic network modules[J].Genome Res,2012,22(2):398-406. [16] Nikiforov YE,Nikiforova MN.Molecular genetics and diagnosis of thyroid cancer[J].Nat Rev Endocrinol,2011,7(10):569-580. [17] Cifuentes-Rojas C,Shippen DE.Telomerase regulation[J].Mutat Res,2012,730(1/2):20-27. [18] Horn S,Figl A,Rachakonda PS,et al.TERT promoter mutations in familial and sporadic melanoma[J].Science,2013,339(6122):959-961. [19] Landa I,Ibrahimpasic T,Boucai L,et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J].J Clin Invest,2016,126(3):1052-1066. [20] Xing M,Liu R,Liu X,et al.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J].J Clin Oncol,2014,32(25):2718-2726. [21] Bullock M,Ren Y,O'Neill C,et al.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas[J].Clin Endocrinol(Oxf),2016,85(2):283-290. [22] Pavelic K,Dedivitis RA,Kapitanovic S,et al.Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions[J].Mutat Res,2006,599(1/2):45-57. [23] Corapcioglu D,Sak SD,Delibasi T,et al.Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas[J].J Transl Med,2006,4:28. [24] Hasbek Z,Turgut B,Erselcan T.p53 antibody:is it an indicator of dedifferentiated thyroid cancer?[J]. Ann Nucl Med,2014,28(1):42-46. [25] Balta AZ,Filiz AI,Kurt Y,et al.Prognostic value of oncoprotein expressions in thyroid papillary carcinoma[J].Med Oncol,2012,29(2):734-741. [26] Tavares C,Melo M,Cameselle-Teijeiro JM,et al.Endocring tumours:Genetic predictors of thyroid cancer outcome[J].Eur J Endocrinol,2016,174(4):R117-126. [27] Omur O,Baran Y.An update on molecular biology of thyroid cancers[J].Crit Rev Oncol Hematol,2014,90(3):233-252. [28] Kalhori V,Tornquist K.MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells[J].Mol Cell Endocrinol,2015,404:113-122. [29] 华特波,孟宪瑛,王广义,等.甲状腺组织中COX-2、MMP-9、VEGF和RET的检测及其在甲状腺乳头状癌早期诊断中的意义[J].吉林大学学报:医学版,2011,37(4):712-717. [30] Gilbert-Sirieix M,Makoukji J,Kimura S,et al.Wnt/beta-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells[J].PLoS One,2011,6(7):e22280. [31] Pacifico F,Leonardi A.Role of NF-kappaB in thyroid cancer[J].Mol Cell Endocrinol,2010,321(1):29-35. [32] Cancer Genome Atlas Research.Integrated genomic characterization of papillary thyroid carcinoma[J].Cell,2014,159(3):676-690. [33] Malapelle U,Bellevicine C,Salatiello M,et al.Sanger sequencing in routine KRAS testing:a review of 1720 cases from a pathologist's perspective[J].J Clin Pathol,2012,65(10):940-944. [34] Schiavo S,Yang WC,Chin NH,et al.Comparison of fluorometric detection methods for quantitative polymerase chain reaction (PCR)[J].J Immunoassay Immunochem,2005,26(1):1-12. [35] Okayama N,Fujimura K,Nakamura J,et al.Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping:tetra-primer amplification refractory mutation system-polymerase chain reaction[J].Clin Chem Lab Med,2004,42(1):13-16. [36] Oler G,Ebina KN,Michaluart PJr,et al.Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis[J].Clin Endocrinol(Oxf),2005,62(4):509-511. [37] Zatelli MC,Trasforini G,Leoni S,et al.BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies[J].Eur J Endocrinol,2009,161(3):467-473. [38] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501. [39] Hsiao SJ,Nikiforov YE.Molecular approaches to thyroid cancer diagnosis[J].Endocrine Relat Cancer,2014,21(5):T301-313. [40] Fenton CL,Lukes Y,Nicholson D,et al.The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults[J].J Clin Endocrinol Metab,2000,85(3):1170-1175. [41] Nikiforov YE.RET/PTC rearrangement in thyroid tumors[J].Endocr Pathol,2002,13(1):3-16. [42] Agarwal S,Agarwal A,Chand G,et al.MEN 2A family——prophylactic thyroidectomy for asymptomatic siblings with positive 634 codon mutation[J].J Assoc Physicians India,2012,60:127-129. [43] Gupta N,Dasyam AK,Carty SE,et al.RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers[J].J Clin Endocrinol Metab,2013,98(5):E914-22. [44] An JH,Song KH,Kim SK,et al.RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma[J].Clin Endocrinol,2015,82(5):760-766. [45] Nikiforov YE.Molecular analysis of thyroid tumors[J].Mod Pathol,2011,24(Suppl 2):S34-S43. [46] Jang EK,Song DE,Sim SY,et al.NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J].Thyroid,2014,24(8):1275-1281. [47] Alzahrani AS,Alsaadi R,Murugan AK,et al.TERT promoter mutations in thyroid cancer[J].Horm Cancer,2016,7(3):165-177. [48] Albarel F,Conte-Devolx B,Oliver C.From nodule to differentiated thyroid carcinoma:contributions of molecular analysis in 2012[J].Ann Endocrinol(Paris),2012,73(3):155-164. |